{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"35.1","value":"186.7"},{"groupId":"OG001","spread":"55.1","value":"203.3"},{"groupId":"OG002","spread":"57.9","value":"218.6"},{"groupId":"OG003","spread":"40.2","value":"171.8"},{"groupId":"OG004","spread":"33.9","value":"182.0"},{"groupId":"OG005","spread":"76.9","value":"146.3"}]}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"42.5","value":"-1.7"},{"groupId":"OG001","spread":"48.6","value":"-11.7"},{"groupId":"OG002","spread":"68.6","value":"-20.0"},{"groupId":"OG003","spread":"42.2","value":"-2.7"},{"groupId":"OG004","spread":"36.3","value":"-39.0"},{"groupId":"OG005","spread":"54.1","value":"-27.0"}]}],"title":"Change from Baseline"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"15"},{"groupId":"OG006","value":"0"}],"units":"Participants"}],"description":"IGF-1R expression was measured in pre- and post-dose skin biopsy samples using an immunohistochemistry (IHC) assay as a function of time and dose. Results were expressed as an IGF-1R membrane H-score which could range from 0 to 300; with a score of 0 representing the absence of IGF-1R expression and an H-score of 300 representing maximum IGF-1R expression. Changes in IGF-1R expression levels from Baseline are summarized for all participants for whom these paired data were available. A post-dose decrease in IGF-1R membrane H-score was an indication of target engagement by dalotuzumab. A larger decrease in H-score correlated with a greater target engagement.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received dalotuzumab 1.25 mg/kg (10 mg/mL) IV infusion Q1W.","id":"OG000","title":"Dalotuzumab 1.25 mg/kg Q1W (10 mg/mL)"},{"description":"Participants received dalotuzumab 2.5 mg/kg (10 mg/mL) IV infusion Q1W.","id":"OG001","title":"Dalotuzumab 2.5 mg/kg Q1W (10 mg/mL)"},{"description":"Participants received dalotuzumab 5 mg/kg (10 mg/mL) IV infusion Q1W.","id":"OG002","title":"Dalotuzumab 5 mg/kg Q1W (10 mg/mL)"},{"description":"Participants received dalotuzumab 10 mg/kg IV infusion Q1W.","id":"OG003","title":"Dalotuzumab 10 mg/kg Q1W (10 mg/mL)"},{"description":"Participants received dalotuzumab 15 mg/kg IV infusion Q1W.","id":"OG004","title":"Dalotuzumab 15 mg/kg Q1W (10 mg/mL)"},{"description":"Participants received dalotuzumab 20 mg/kg IV infusion Q1W or Q2W.","id":"OG005","title":"Dalotuzumab 20 mg/kg Q1W (10 mg/mL)"},{"description":"Participants received dalotuzumab 30 mg/kg (20 mg/mL) IV infusion Q3W.","id":"OG006","title":"Dalotuzumab 30 mg/kg Q3W (20 mg/mL)"}],"paramType":"MEAN","populationDescription":"The population consisted of all evaluable participants who received \\>90% of intended drug volume and had skin IGF-1R pharmacodynamics measurements at Baseline and at least once during treatment. No data were available for the Dalotuzumab 30 mg/kg Q3W treatment group.","reportingStatus":"POSTED","timeFrame":"Predose in Cycle 1 (Baseline) and predose in Cycle 3 (Week 4)","title":"Change From Baseline in Insulin-like Growth Factor Receptor Type 1 (IGF-1R) Protein Expression Level H-score in Skin Samples","type":"SECONDARY","unitOfMeasure":"H-score"}